- Home
- TBHC vs SER Comparison
TBHC vs SER Comparison
Compare TBHC & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBHC | SER |
|---|---|---|
| Founded | 1966 | 2017 |
| Country | United States | United States |
| Employees | 4010 | 13 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 19.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TBHC | SER |
|---|---|---|
| Price | $0.92 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 45.7K | ★ 102.1K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $1.22 |
| 52 Week High | $2.40 | $7.92 |
Technical Indicators
Market Signals| Indicator | TBHC | SER |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 46.18 |
| Support Level | N/A | $1.85 |
| Resistance Level | $1.27 | $2.30 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 47.00 | 36.00 |
Price Performance
Historical ComparisonAbout TBHC The Brand House Collective Inc.
The Brand House Collective Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.